Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    lu002
Previous Study | Return to List | Next Study

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03137771
Recruitment Status : Recruiting
First Posted : May 3, 2017
Last Update Posted : June 20, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
NRG Oncology

Brief Summary:
This randomized phase II/III trial studies how well giving maintenance chemotherapy with or without local consolidation therapy works in treating patients with stage IV non-small cell lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium, erlotinib hydrochloride, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Local consolidation therapy such as radiation/stereotactic body radiation or surgery may kill cancer cells left after initial treatment. Giving maintenance chemotherapy and local consolidation therapy together may work better than maintenance chemotherapy alone in treating patients with stage IV non-small cell lung cancer.

Condition or disease Intervention/treatment Phase
Recurrent Non-Small Cell Lung Carcinoma Stage IV Non-Small Cell Lung Cancer Radiation: 3-Dimensional Conformal Radiation Therapy (3D-CRT) Drug: Docetaxel Drug: Gemcitabine Radiation: Intensity-Modulated Radiation Therapy (IMRT) Drug: Pemetrexed Disodium Radiation: Stereotactic Body Radiation Therapy (SBRT) Drug: Erlotinib Hydrochloride Drug: Pembrolizumab Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

Phase II

To evaluate the impact of adding local consolidative therapy (LCT) to maintenance systemic therapy versus maintenance systemic therapy alone on progression-free survival for patients with metastatic non-small cell lung cancer (NSCLC) with no evidence of progression and limited metastatic sites after first-line systemic therapy.

Phase III

To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance systemic therapy alone on overall survival for patients with metastatic NSCLC with no evidence of progression and limited metastatic sites after first-line systemic therapy.

SECONDARY OBJECTIVES:

I. To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance systemic therapy alone on in-field local failure.

II. To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance systemic therapy alone on the time to development of new lesions.

III. To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance systemic therapy alone on toxicity.

IV. To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance systemic therapy alone on duration of maintenance systemic therapy usage.

V. To evaluate the effect of adding LCT to systemic therapy in limited stage IV NSCLC on Quality of Life (QOL) VI. To collect biospecimens and evaluate the correlation between clinical outcomes and circulating tumor DNA (ctDNA).

OUTLINE: Patients are randomized into 1 of 2 arms.

ARM 1 (CHEMOTHERAPY ALONE): ): Patients may receive docetaxel intravenously (IV) over 60 minutes on Day 1, erlotinib hydrochloride orally (PO) once daily (QD), or gemcitabine IV over 30 minutes on Days 1 and 8. Patients with non-squamous non-small cell lung cancer may receive pemetrexed disodium IV over 10 minutes on Day 1 alone or in combination with pembrolizumab IV over 30 minutes. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

ARM 2 (SBRT AND CHEMOTHERAPY): Patients undergo LCT over 2-4 weeks. If LCT cannot be used to treat primary disease sites, patients also undergo intensity-modulated radiation therapy (IMRT) or 3-dimensional conformal radiation therapy (3DCRT) over 3-5 weeks. Within 2 weeks after completion of radiation therapy, patients receive chemotherapy as in Arm 1. Patients may possibly undergo surgery.

After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, then annually thereafter.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Actual Study Start Date : April 7, 2017
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : April 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Active Comparator: Arm 1 (maintenance chemotherapy)
Patients may receive docetaxel IV over 60 minutes on day 1, erlotinib hydrochloride PO QD, or gemcitabine IV over 30 minutes on days 1 and 8. Patients with non-squamous non-small cell lung cancer may receive pemetrexed disodium IV over 10 minutes on day 1 alone or in combination with pembrolizumab IV over 30 minutes. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Drug: Docetaxel
Given IV
Other Names:
  • Docecad
  • RP56976
  • Taxotere
  • Taxotere Injection Concentrate

Drug: Gemcitabine
Given IV
Other Names:
  • dFdC
  • dFdCyd
  • Difluorodeoxycytidine

Drug: Pemetrexed Disodium
Given IV
Other Names:
  • Alimta
  • LY231514
  • N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt

Drug: Erlotinib Hydrochloride
Given PO
Other Name: Tarceva

Drug: Pembrolizumab
Given IV
Other Name: Keytruda

Experimental: Arm 2 (SBRT + maintenance chemotherapy)
Patients undergo LCT over 2-4 weeks. If LCT cannot be used to treat primary disease sites, patients also undergo IMRT or 3DCRT over 3-5 weeks. Within 2 weeks after completion of radiation therapy, patients receive chemotherapy as in Arm 1. Patients may possibly undergo surgery.
Radiation: 3-Dimensional Conformal Radiation Therapy (3D-CRT)
Undergo 3DCRT
Other Names:
  • 3-dimensional conformal radiation therapy
  • 3-dimensional radiation therapy
  • 3D CONFORMAL RADIATION THERAPY
  • 3D CRT
  • 3D-CRT
  • Conformal Therapy
  • Radiation Conformal Therapy

Drug: Docetaxel
Given IV
Other Names:
  • Docecad
  • RP56976
  • Taxotere
  • Taxotere Injection Concentrate

Drug: Gemcitabine
Given IV
Other Names:
  • dFdC
  • dFdCyd
  • Difluorodeoxycytidine

Radiation: Intensity-Modulated Radiation Therapy (IMRT)
Undergo IMRT
Other Names:
  • IMRT
  • Intensity Modulated RT
  • INTENSITY-MODULATED RADIATION THERAPY
  • Intensity-Modulated Radiotherapy

Drug: Pemetrexed Disodium
Given IV
Other Names:
  • Alimta
  • LY231514
  • N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt

Radiation: Stereotactic Body Radiation Therapy (SBRT)
Undergo SBRT
Other Names:
  • SBRT
  • stereotactic body radiation therapy

Drug: Erlotinib Hydrochloride
Given PO
Other Name: Tarceva

Drug: Pembrolizumab
Given IV
Other Name: Keytruda




Primary Outcome Measures :
  1. Phase II - Progression-Free Survival (PFS) [ Time Frame: From the time of randomization to date any documented progression or death due to any cause, whichever occurs first. Assessed for up to 3 years. ]
    Progression-Free Survival

  2. Phase III - Overall Survival (OS) [ Time Frame: From the time of randomization to date of death due to any cause. Assessed up to 3 years. ]
    Overall Survival


Secondary Outcome Measures :
  1. Time to In-Field Failure [ Time Frame: Time from randomization to progression within the irradiated field at any time, assessed for up to 3 years ]
    The time it takes for disease progression to occur within the radiation treatment field of disease will be measured.

  2. Incidence of adverse events graded per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5 [ Time Frame: Up to 3 years ]
    Will be reported with the frequency and severity (e.g., type, grade, and attribution) by arm.

  3. Duration of Maintenance Chemotherapy Usage [ Time Frame: Up to 3 years ]
    Will be performed on an intent to treat basis.

  4. Time to Development of New Lesions [ Time Frame: Time from randomization to the first occurrence of any new lesions that have not been treated with local consolidative therapy, assessed for up to 3 years ]
    Will be performed on an intent to treat basis.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up
  • Women of childbearing potential and men who are sexually active should be willing and able to use medically acceptable forms of contraception during the trial and for up to 180 days after completion of all treatment to prevent pregnancy or fathering a child.
  • Pathologically proven diagnosis of NSCLC, with metastases (stage IV disease) present prior to registration; this includes patients newly diagnosed with metastatic disease or those initially diagnosed and treated for stage I-III NSCLC who ultimately develop metastases
  • Appropriate stage for study entry based on the following diagnostic workup:

    • History/physical examination within 30 days prior to registration
    • Imaging proof of limited metastatic disease and response to therapy/stable disease, by at least CT chest through the adrenals or PET/CT within 30 days prior to registration
  • Zubrod performance status 0, 1, or 2 within 30 days prior to registration
  • Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × upper limit of normal (ULN) or ≤ 5 × ULN with metastatic liver disease
  • Total bilirubin ≤ 1.5 × ULN
  • Absolute neutrophil count (ANC) ≥ 500 cells/mm^3
  • Creatinine clearance ≥ 45 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
  • Platelets ≥ 50,000 cells/mm^3
  • Negative serum pregnancy test within one week prior to registration for females of childbearing potential
  • Patients must have received first-line/induction chemotherapy (4 cycles) and achieved stable disease or a partial response
  • Prior systemic chemotherapy as part of concurrent treatment approach for previously diagnosed stage III NSCLC, as adjuvant therapy for previously resected NSCLC, or for other previous cancers is permitted
  • Prior radiotherapy for patients with brain metastases prior to enrollment is acceptable
  • Patients must have measurable disease at baseline and 3 or fewer discrete, extracranial metastatic disease sites that are technically amenable to SBRT
  • For de novo stage IV NSCLC patients (patients with metastatic disease at first presentation), primary disease must be treatable with local therapy in the form of SBRT or hypofractionated radiation; if the primary disease is found in the peripheral or central lung parenchyma without nodal disease for instance, SBRT may be employed; if primary disease is more advanced with involvement of the mediastinum (T4 tumor, N1-N3 disease, etc.), these volumes should be technically treatable with hypofractionated radiation
  • If primary disease in the thoracic cavity was previously treated with local therapy in the form of surgery, any local/regional disease recurrence should be technically treatable with SBRT or hypofractionated radiation after induction systemic therapy
  • Patients must be registered within 35 days of administration of the last dose of first-line/induction systemic therapy
  • The patient or a legally authorized representative must provide study-specific informed consent prior to study entry
  • Patients with brain metastases are eligible if these lesions have been previously treated and the patients have no clinical or radiographic evidence of progression prior to enrollment

Exclusion Criteria:

  • Clinical or radiologic evidence of untreated and/or progressive brain metastases
  • Cutaneous metastasis of NSCLC
  • Metastatic disease invading the esophagus, stomach, intestines, or mesenteric lymph nodes if not a candidate for surgery for these lesions
  • Prior invasive malignancy (except non-melanomatous skin cancer, low or intermediate risk prostate cancer, or in situ carcinoma of breast, oral cavity, skin, or cervix) unless disease free for a minimum of one year
  • Metastases located within 3 cm of previously irradiated (< 3Gy per fraction) structures if if not a candidate for surgery for these lesions and if:

    • Spinal cord previously irradiated to > 40 Gy
    • Brachial plexus previously irradiated to > 50 Gy
    • Small intestine, large intestine, or stomach previously irradiated to > 45 Gy
    • Brainstem previously irradiated to > 50 Gy
    • Lung previously irradiated with prior V20 Gy > 35%
  • Patients receiving targeted therapy (non-cytotoxic systemic therapy) for NSCLC in the first-line setting
  • If a patient has progressed in previous areas of primary disease that received definitive doses of radiation, these patients would require re-irradiation in previous high dose anatomic areas and are not eligible for this study
  • Patients with malignant pleural effusions that do not resolve after first-line systemic therapy; patients with pleural effusions that have become too small for thoracentesis at the time of registration would be permitted on study, indicating a significant response to first-line chemotherapy
  • Patients with more than 3 discrete locations of extra-cranial metastatic disease after first-line systemic therapy requiring more than 3 SBRT plans to cover these distinct metastatic disease entities
  • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
  • Patients who are pregnant or nursing
  • Participation in any investigational drug study (excluding non-oncology and/or symptom management studies) within 4 weeks prior to registration
  • Known human immunodeficiency virus (HIV) positive with cluster of differentiation 4 (CD4) count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count ≥ 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol
  • Patients who received prior non-induction pembrolizumab, patients on chronic steroids or who have active autoimmune disease for which they received systemic treatment in the previous 2 years with corticosteroids, disease modifying agents, or immunosuppressive drugs. Replacement therapy (thyroxine, insulin or physiological corticosteroid replacement for adrenal or pituitary insufficiency) is allowed. Patients with active interstitial lung disease or who have a history of pneumonitis for which they had received glucocorticoids are not eligible
  • Prior bevacizumab therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03137771


  Hide Study Locations
Locations
Layout table for location information
United States, Arizona
Arizona Breast Cancer Specialists-Gilbert Recruiting
Gilbert, Arizona, United States, 85297
Contact: Site Public Contact    480-922-4600      
Principal Investigator: Christopher A. Biggs         
Arizona Center for Cancer Care-Peoria Recruiting
Peoria, Arizona, United States, 85381
Contact: Site Public Contact    623-773-2873      
Principal Investigator: Christopher A. Biggs         
Mayo Clinic Hospital Recruiting
Phoenix, Arizona, United States, 85054
Contact: Site Public Contact    855-776-0015      
Principal Investigator: Helen J. Ross         
Arizona Breast Cancer Specialists-Scottsdale Recruiting
Scottsdale, Arizona, United States, 85258
Contact: Site Public Contact    480-922-4600      
Principal Investigator: Christopher A. Biggs         
Mayo Clinic in Arizona Recruiting
Scottsdale, Arizona, United States, 85259
Contact: Site Public Contact    855-776-0015      
Principal Investigator: Helen J. Ross         
University of Arizona Cancer Center-Orange Grove Campus Recruiting
Tucson, Arizona, United States, 85704
Contact: Site Public Contact    520-694-8900      
Principal Investigator: Charles C. Hsu         
Banner University Medical Center - Tucson Recruiting
Tucson, Arizona, United States, 85719
Contact: Site Public Contact       aselegue@email.arizona.edu   
Principal Investigator: Charles C. Hsu         
United States, Arkansas
University of Arkansas for Medical Sciences Recruiting
Little Rock, Arkansas, United States, 72205
Contact: Site Public Contact    501-686-8274      
Principal Investigator: Sanjay Maraboyina         
United States, California
Alta Bates Summit Medical Center-Herrick Campus Recruiting
Berkeley, California, United States, 94704
Contact: Site Public Contact    415-209-2686    bernicl@sutterhealth.org   
Principal Investigator: Christopher U. Jones         
City of Hope Comprehensive Cancer Center Recruiting
Duarte, California, United States, 91010
Contact: Site Public Contact    800-826-4673    becomingapatient@coh.org   
Principal Investigator: Sagus Sampath         
UC San Diego Moores Cancer Center Recruiting
La Jolla, California, United States, 92093
Contact: Site Public Contact    858-822-5354    cancercto@ucsd.edu   
Principal Investigator: James J. Urbanic         
Los Angeles County-USC Medical Center Recruiting
Los Angeles, California, United States, 90033
Contact: Site Public Contact    323-865-0451      
Principal Investigator: Jason C. Ye         
USC / Norris Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90033
Contact: Site Public Contact    323-865-0451      
Principal Investigator: Jason C. Ye         
Saint Joseph Hospital - Orange Recruiting
Orange, California, United States, 92868
Contact: Site Public Contact    714-734-6220      
Principal Investigator: Robert B. Ash         
The Permanente Medical Group-Roseville Radiation Oncology Recruiting
Roseville, California, United States, 95678
Contact: Site Public Contact    877-642-4691    Kpoct@kp.org   
Principal Investigator: Samantha A. Seaward         
Sutter Medical Center Sacramento Recruiting
Sacramento, California, United States, 95816
Contact: Site Public Contact    916-454-6500    cancerinfo@sutterhealth.org   
Principal Investigator: Christopher U. Jones         
University of California Davis Comprehensive Cancer Center Recruiting
Sacramento, California, United States, 95817
Contact: Site Public Contact    916-734-3089      
Principal Investigator: Megan E. Daly         
Saint Helena Hospital Recruiting
Saint Helena, California, United States, 94574
Contact: Site Public Contact    707-967-3698      
Principal Investigator: David J. Tate         
City of Hope South Pasadena Recruiting
South Pasadena, California, United States, 91030
Contact: Site Public Contact    800-826-4673    becomingapatient@coh.org   
Principal Investigator: Sagus Sampath         
Kaiser Permanente Cancer Treatment Center Recruiting
South San Francisco, California, United States, 94080
Contact: Site Public Contact    877-642-4691    Kpoct@kp.org   
Principal Investigator: Samantha A. Seaward         
Gene Upshaw Memorial Tahoe Forest Cancer Center Recruiting
Truckee, California, United States, 96161
Contact: Site Public Contact    530-582-6450      
Principal Investigator: Megan E. Daly         
United States, Colorado
Penrose-Saint Francis Healthcare Recruiting
Colorado Springs, Colorado, United States, 80907
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
UCHealth Memorial Hospital Central Recruiting
Colorado Springs, Colorado, United States, 80909
Contact: Site Public Contact    719-365-2406      
Principal Investigator: Robert J. Hoyer         
Poudre Valley Hospital Suspended
Fort Collins, Colorado, United States, 80524
United States, Connecticut
Yale University Recruiting
New Haven, Connecticut, United States, 06520
Contact: Site Public Contact    203-785-5702    canceranswers@yale.edu   
Principal Investigator: Roy H. Decker         
United States, Delaware
Helen F Graham Cancer Center Recruiting
Newark, Delaware, United States, 19713
Contact: Site Public Contact    302-623-4450    KDempsey@christianacare.org   
Principal Investigator: Gregory A. Masters         
Beebe Health Campus Recruiting
Rehoboth Beach, Delaware, United States, 19971
Contact: Site Public Contact    302-645-3100    Dmiskin@Beebehealthcare.org   
Principal Investigator: Gregory A. Masters         
United States, Florida
UM Sylvester Comprehensive Cancer Center at Deerfield Beach Recruiting
Deerfield Beach, Florida, United States, 33442
Contact: Site Public Contact    305-243-2647      
Principal Investigator: Raphael L. Yechieli         
University of Florida Health Science Center - Gainesville Active, not recruiting
Gainesville, Florida, United States, 32610
Mayo Clinic in Florida Recruiting
Jacksonville, Florida, United States, 32224-9980
Contact: Site Public Contact    855-776-0015      
Principal Investigator: Helen J. Ross         
University of Miami Miller School of Medicine-Sylvester Cancer Center Recruiting
Miami, Florida, United States, 33136
Contact: Site Public Contact    305-243-2647      
Principal Investigator: Raphael L. Yechieli         
UF Cancer Center at Orlando Health Recruiting
Orlando, Florida, United States, 32806
Contact: Site Public Contact    321-841-7246    CancerClinicalTrials@orlandohealth.com   
Principal Investigator: Justin M. Rineer         
Tallahassee Memorial HealthCare Recruiting
Tallahassee, Florida, United States, 32308
Contact: Site Public Contact    850-431-0673      
Principal Investigator: Karen B. Russell         
Moffitt Cancer Center Recruiting
Tampa, Florida, United States, 33612
Contact: Site Public Contact    800-679-0775    canceranswers@moffitt.org   
Principal Investigator: Bradford A. Perez         
Cleveland Clinic-Weston Recruiting
Weston, Florida, United States, 33331
Contact: Site Public Contact    954-659-5705    CancerAnswer@ccf.org   
Principal Investigator: Gregory M. M. Videtic         
United States, Georgia
Grady Health System Recruiting
Atlanta, Georgia, United States, 30303
Contact: Site Public Contact    404-489-9164      
Principal Investigator: Kristin A. Higgins         
Emory University Hospital Midtown Recruiting
Atlanta, Georgia, United States, 30308
Contact: Site Public Contact    888-946-7447      
Principal Investigator: Kristin A. Higgins         
Emory University Hospital/Winship Cancer Institute Recruiting
Atlanta, Georgia, United States, 30322
Contact: Site Public Contact    404-778-1868      
Principal Investigator: Kristin A. Higgins         
Emory Saint Joseph's Hospital Recruiting
Atlanta, Georgia, United States, 30342
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Kristin A. Higgins         
Augusta University Medical Center Recruiting
Augusta, Georgia, United States, 30912
Contact: Site Public Contact    706-721-2388    ga_cares@augusta.edu   
Principal Investigator: Sharad A. Ghamande         
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler Recruiting
Savannah, Georgia, United States, 31405
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Howard A. Zaren         
United States, Hawaii
Queen's Medical Center Active, not recruiting
Honolulu, Hawaii, United States, 96813
The Cancer Center of Hawaii-Liliha Active, not recruiting
Honolulu, Hawaii, United States, 96817
United States, Illinois
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
Contact: Site Public Contact    312-695-1301    cancer@northwestern.edu   
Principal Investigator: Timothy J. Kruser         
University of Illinois Recruiting
Chicago, Illinois, United States, 60612
Contact: Site Public Contact    312-355-3046      
Principal Investigator: Lawrence E. Feldman         
Decatur Memorial Hospital Recruiting
Decatur, Illinois, United States, 62526
Contact: Site Public Contact    217-876-4740    rhamrick@dmhhs.org   
Principal Investigator: Bryan A. Faller         
Crossroads Cancer Center Recruiting
Effingham, Illinois, United States, 62401
Contact: Site Public Contact    217-876-4740    rhamrick@dmhhs.org   
Principal Investigator: Bryan A. Faller         
Edward Hines Jr VA Hospital Recruiting
Hines, Illinois, United States, 60141
Contact: Site Public Contact    708-202-8387      
Principal Investigator: Matthew M. Harkenrider         
Condell Memorial Hospital Recruiting
Libertyville, Illinois, United States, 60048
Contact: Site Public Contact    630-929-6129    advocateresearch@advocatehealth.com   
Principal Investigator: Dean J. Conterato         
Loyola University Medical Center Recruiting
Maywood, Illinois, United States, 60153
Contact: Site Public Contact    708-226-4357      
Principal Investigator: Matthew M. Harkenrider         
Methodist Medical Center of Illinois Recruiting
Peoria, Illinois, United States, 61636
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
OSF Saint Francis Medical Center Recruiting
Peoria, Illinois, United States, 61637
Contact: Site Public Contact    309-243-3605    andersonj@illinoiscancercare.com   
Principal Investigator: Bryan A. Faller         
Memorial Medical Center Recruiting
Springfield, Illinois, United States, 62781
Contact: Site Public Contact    217-788-3528      
Principal Investigator: Bryan A. Faller         
Southwest Illinois Health Services LLP Recruiting
Swansea, Illinois, United States, 62226
Contact: Site Public Contact    618-236-1000    lynns@thecancercenter.com   
Principal Investigator: Bryan A. Faller         
Carle Cancer Center Recruiting
Urbana, Illinois, United States, 61801
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: Daniel H. Barnett         
United States, Indiana
Parkview Hospital Randallia Active, not recruiting
Fort Wayne, Indiana, United States, 46805
Parkview Regional Medical Center Recruiting
Fort Wayne, Indiana, United States, 46845
Contact: Site Public Contact    877-784-4673      
Principal Investigator: Brian K. Chang         
Goshen Center for Cancer Care Recruiting
Goshen, Indiana, United States, 46526
Contact: Site Public Contact    574-364-2973    cccois@goshenhealth.com   
Principal Investigator: Houman Vaghefi         
Community Cancer Center East Recruiting
Indianapolis, Indiana, United States, 46219
Contact: Site Public Contact    800-777-7775    lcheri@ecommunity.com   
Principal Investigator: Daniel W. Weed         
Community Cancer Center South Recruiting
Indianapolis, Indiana, United States, 46227
Contact: Site Public Contact    317-497-2823    lcheri@ecommunity.com   
Principal Investigator: Daniel W. Weed         
Franciscan Health Indianapolis Recruiting
Indianapolis, Indiana, United States, 46237
Contact: Site Public Contact    317-528-7060      
Principal Investigator: Michael S. Eaton         
Community Cancer Center North Recruiting
Indianapolis, Indiana, United States, 46256
Contact: Site Public Contact    317-621-7104    lcheri@ecommunity.com   
Principal Investigator: Daniel W. Weed         
Franciscan Health Mooresville Recruiting
Mooresville, Indiana, United States, 46158
Contact: Site Public Contact    317-834-3603      
Principal Investigator: Michael S. Eaton         
United States, Iowa
Iowa Methodist Medical Center Recruiting
Des Moines, Iowa, United States, 50309
Contact: Site Public Contact    515-241-6727      
Principal Investigator: Robert J. Behrens         
United States, Kansas
University of Kansas Cancer Center Active, not recruiting
Kansas City, Kansas, United States, 66160
Lawrence Memorial Hospital Recruiting
Lawrence, Kansas, United States, 66044
Contact: Site Public Contact    316-268-5374    Keisha.humphries@ascension.org   
Principal Investigator: Pavan S. Reddy         
University of Kansas Cancer Center-Overland Park Active, not recruiting
Overland Park, Kansas, United States, 66210
Via Christi Regional Medical Center Recruiting
Wichita, Kansas, United States, 67214
Contact: Site Public Contact    800-362-0070    Keisha.humphries@ascension.org   
Principal Investigator: Pavan S. Reddy         
United States, Kentucky
Saint Elizabeth Medical Center South Recruiting
Edgewood, Kentucky, United States, 41017
Contact: Site Public Contact    859-301-5473    darla.hehman@stelizabeth.com   
Principal Investigator: Colleen M. Darnell         
Norton Hospital Pavilion and Medical Campus Recruiting
Louisville, Kentucky, United States, 40202
Contact: Site Public Contact    502-629-2500      
Principal Investigator: Yong I. Cha         
The James Graham Brown Cancer Center at University of Louisville Recruiting
Louisville, Kentucky, United States, 40202
Contact: Site Public Contact    502-562-3429      
Principal Investigator: Neal E. Dunlap         
United States, Louisiana
LSU Health Baton Rouge-North Clinic Recruiting
Baton Rouge, Louisiana, United States, 70805
Contact: Site Public Contact    225-215-1353    clinicalresearch@marybird.com   
Principal Investigator: David S. Hanson         
Louisiana Hematology Oncology Associates LLC Recruiting
Baton Rouge, Louisiana, United States, 70809
Contact: Site Public Contact    225-215-1353    clinicalresearch@marybird.com   
Principal Investigator: David S. Hanson         
Mary Bird Perkins Cancer Center Recruiting
Baton Rouge, Louisiana, United States, 70809
Contact: Site Public Contact    225-215-1353    clinicalresearch@marybird.com   
Principal Investigator: David S. Hanson         
Our Lady of the Lake Physicians Group - Medical Oncology Recruiting
Baton Rouge, Louisiana, United States, 70809
Contact: Site Public Contact    225-757-0343    clinicalresearch@marybird.com   
Principal Investigator: David S. Hanson         
United States, Maryland
University of Maryland/Greenebaum Cancer Center Recruiting
Baltimore, Maryland, United States, 21201
Contact: Site Public Contact    800-888-8823      
Principal Investigator: Pranshu Mohindra         
Central Maryland Radiation Oncology in Howard County Recruiting
Columbia, Maryland, United States, 21044
Contact: Site Public Contact    443-546-1300      
Principal Investigator: Pranshu Mohindra         
UM Baltimore Washington Medical Center/Tate Cancer Center Recruiting
Glen Burnie, Maryland, United States, 21061
Contact: Site Public Contact    410-553-8100      
Principal Investigator: Pranshu Mohindra         
Richard A Henson Cancer Institute at Ocean Pines Recruiting
Ocean Pines, Maryland, United States, 21811
Contact: Site Public Contact    410-543-7017    stephanie.cason@peninsula.org   
Principal Investigator: John R. Mansueti         
Peninsula Regional Medical Center Recruiting
Salisbury, Maryland, United States, 21801
Contact: Site Public Contact    866-922-6237      
Principal Investigator: John R. Mansueti         
United States, Massachusetts
Boston Medical Center Recruiting
Boston, Massachusetts, United States, 02118
Contact: Site Public Contact    617-638-8265      
Principal Investigator: Kimberley S. Mak         
Lahey Hospital and Medical Center Recruiting
Burlington, Massachusetts, United States, 01805
Contact: Site Public Contact    781-744-8027      
Principal Investigator: Paul J. Hesketh         
United States, Michigan
McLaren Cancer Institute-Bay City Recruiting
Bay City, Michigan, United States, 48706
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Steven R. Miller         
McLaren Cancer Institute-Clarkston Recruiting
Clarkston, Michigan, United States, 48346
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Steven R. Miller         
Henry Ford Macomb Hospital-Clinton Township Recruiting
Clinton Township, Michigan, United States, 48038
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Eleanor M. Walker         
Wayne State University/Karmanos Cancer Institute Recruiting
Detroit, Michigan, United States, 48201
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Steven R. Miller         
Henry Ford Hospital Recruiting
Detroit, Michigan, United States, 48202
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Eleanor M. Walker         
Weisberg Cancer Treatment Center Recruiting
Farmington Hills, Michigan, United States, 48334
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Steven R. Miller         
McLaren Cancer Institute-Flint Recruiting
Flint, Michigan, United States, 48532
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Steven R. Miller         
Singh and Arora Hematology Oncology PC Recruiting
Flint, Michigan, United States, 48532
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Steven R. Miller         
West Michigan Cancer Center Recruiting
Kalamazoo, Michigan, United States, 49007
Contact: Site Public Contact    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
McLaren-Greater Lansing Recruiting
Lansing, Michigan, United States, 48910
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Steven R. Miller         
Mid-Michigan Physicians-Lansing Recruiting
Lansing, Michigan, United States, 48912
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Steven R. Miller         
McLaren Cancer Institute-Macomb Recruiting
Mount Clemens, Michigan, United States, 48043
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Steven R. Miller         
McLaren Cancer Institute-Northern Michigan Recruiting
Petoskey, Michigan, United States, 49770
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Steven R. Miller         
McLaren-Port Huron Recruiting
Port Huron, Michigan, United States, 48060
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Steven R. Miller         
United States, Minnesota
Sanford Joe Lueken Cancer Center Recruiting
Bemidji, Minnesota, United States, 56601
Contact: Site Public Contact    218-333-5000    OncologyClinicalTrialsFargo@sanfordhealth.org   
Principal Investigator: Preston D. Steen         
Saint Luke's Hospital of Duluth Recruiting
Duluth, Minnesota, United States, 55805
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Steven R. Bonin         
Regions Hospital Recruiting
Saint Paul, Minnesota, United States, 55101
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Paul W. Sperduto         
United States, Missouri
Saint Francis Medical Center Recruiting
Cape Girardeau, Missouri, United States, 63703
Contact: Site Public Contact    573-334-2230    sfmc@sfmc.net   
Principal Investigator: Bryan A. Faller         
Kansas City Veterans Affairs Medical Center Recruiting
Kansas City, Missouri, United States, 64128
Contact: Site Public Contact    800-525-1483      
Principal Investigator: John H. Park         
Delbert Day Cancer Institute at PCRMC Recruiting
Rolla, Missouri, United States, 65401
Contact: Site Public Contact    573-458-7504    jrichards@research.pcrmc.com   
Principal Investigator: Jay W. Carlson         
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Site Public Contact    800-600-3606    info@siteman.wustl.edu   
Principal Investigator: Clifford G. Robinson         
Missouri Baptist Medical Center Recruiting
Saint Louis, Missouri, United States, 63131
Contact: Site Public Contact    314-996-5569      
Principal Investigator: Bryan A. Faller         
Mercy Hospital Saint Louis Recruiting
Saint Louis, Missouri, United States, 63141
Contact: Site Public Contact    314-251-7066      
Principal Investigator: Jay W. Carlson         
United States, Montana
Benefis Healthcare- Sletten Cancer Institute Recruiting
Great Falls, Montana, United States, 59405
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: Benjamin T. Marchello         
Kalispell Regional Medical Center Recruiting
Kalispell, Montana, United States, 59901
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: Benjamin T. Marchello         
United States, Nebraska
Alegent Health Bergan Mercy Medical Center Recruiting
Omaha, Nebraska, United States, 68124
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
United States, Nevada
Renown Regional Medical Center Recruiting
Reno, Nevada, United States, 89502
Contact: Site Public Contact    702-384-0013    research@sncrf.org   
Principal Investigator: John A. Ellerton         
United States, New Hampshire
Wentworth-Douglass Hospital Recruiting
Dover, New Hampshire, United States, 03820
Contact: Site Public Contact    603-740-2150      
Principal Investigator: Arul Mahadevan         
United States, New Jersey
Virtua Memorial Active, not recruiting
Mount Holly, New Jersey, United States, 08060
Community Medical Center Recruiting
Toms River, New Jersey, United States, 08755
Contact: Site Public Contact    732-818-3882      
Principal Investigator: David J. D'Ambrosio         
Virtua Voorhees Active, not recruiting
Voorhees, New Jersey, United States, 08043
United States, New Mexico
Lovelace Medical Center-Saint Joseph Square Active, not recruiting
Albuquerque, New Mexico, United States, 87102
University of New Mexico Cancer Center Active, not recruiting
Albuquerque, New Mexico, United States, 87102
Lovelace Radiation Oncology Active, not recruiting
Albuquerque, New Mexico, United States, 87109
Christus Saint Vincent Regional Cancer Center Active, not recruiting
Santa Fe, New Mexico, United States, 87505
United States, New York
Montefiore Medical Center-Einstein Campus Suspended
Bronx, New York, United States, 10461
Montefiore Medical Center - Moses Campus Recruiting
Bronx, New York, United States, 10467
Contact: Site Public Contact    718-379-6866    aaraiza@montefiore.org   
Principal Investigator: Nitin Ohri         
New York-Presbyterian/Brooklyn Methodist Hospital Recruiting
Brooklyn, New York, United States, 11215
Contact: Site Public Contact    718-780-3677    Adg9003@nyp.org   
Principal Investigator: Hani L. Ashamalla         
Mount Sinai Hospital Recruiting
New York, New York, United States, 10029
Contact: Site Public Contact    212-824-7309    CCTO@mssm.edu   
Principal Investigator: Kenneth E. Rosenzweig         
University of Rochester Recruiting
Rochester, New York, United States, 14642
Contact: Site Public Contact    585-275-5830      
Principal Investigator: Yuhchyau Chen         
Stony Brook University Medical Center Recruiting
Stony Brook, New York, United States, 11794
Contact: Site Public Contact    800-862-2215      
Principal Investigator: Kartik M. Mani         
State University of New York Upstate Medical University Recruiting
Syracuse, New York, United States, 13210
Contact: Site Public Contact    315-464-5476      
Principal Investigator: Michael D. Mix         
Dickstein Cancer Treatment Center Active, not recruiting
White Plains, New York, United States, 10601
United States, North Carolina
Atrium Health University City/LCI-University Recruiting
Charlotte, North Carolina, United States, 28262
Contact: Site Public Contact    800-804-9376      
Principal Investigator: Daniel R. Carrizosa         
Atrium Health Cabarrus/LCI-Concord Recruiting
Concord, North Carolina, United States, 28025
Contact: Site Public Contact    704-403-1520      
Principal Investigator: Daniel R. Carrizosa         
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Site Public Contact    888-275-3853      
Principal Investigator: Thomas E. Stinchcombe         
CarolinaEast Medical Center Recruiting
New Bern, North Carolina, United States, 28561
Contact: Site Public Contact    252-634-6589    lharrison@carolinaeasthealth.com   
Principal Investigator: Svetlana S. Kats         
NHRMC Radiation Oncology - Supply Recruiting
Supply, North Carolina, United States, 28462
Contact: Site Public Contact    910-754-4716      
Principal Investigator: Michael A. Papagikos         
New Hanover Regional Medical Center/Zimmer Cancer Center Recruiting
Wilmington, North Carolina, United States, 28401
Contact: Site Public Contact    910-342-3000      
Principal Investigator: Michael A. Papagikos         
NHRMC Radiation Oncology - 16th Street Recruiting
Wilmington, North Carolina, United States, 28401
Contact: Site Public Contact    910-251-1839      
Principal Investigator: Michael A. Papagikos         
United States, North Dakota
Sanford Bismarck Medical Center Recruiting
Bismarck, North Dakota, United States, 58501
Contact: Site Public Contact    701-323-5760    OncologyClinicalTrialsFargo@sanfordhealth.org   
Principal Investigator: Preston D. Steen         
Sanford Roger Maris Cancer Center Recruiting
Fargo, North Dakota, United States, 58122
Contact: Site Public Contact    701-234-6161    OncologyClinicalTrialsFargo@sanfordhealth.org   
Principal Investigator: Preston D. Steen         
United States, Ohio
Cleveland Clinic Akron General Recruiting
Akron, Ohio, United States, 44307
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Mitchel L. Fromm         
Adena Regional Medical Center Recruiting
Chillicothe, Ohio, United States, 45601
Contact: Site Public Contact    877-779-7585    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
University of Cincinnati/Barrett Cancer Center Recruiting
Cincinnati, Ohio, United States, 45219
Contact: Site Public Contact    513-558-4553    uchealthnews@uc.edu   
Principal Investigator: Emily C. Daugherty         
Case Western Reserve University Recruiting
Cleveland, Ohio, United States, 44106
Contact: Site Public Contact    800-641-2422    CTUReferral@UHhospitals.org   
Principal Investigator: Mitchell Machtay         
Cleveland Clinic Cancer Center/Fairview Hospital Recruiting
Cleveland, Ohio, United States, 44111
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Gregory M. M. Videtic         
Cleveland Clinic Foundation Recruiting
Cleveland, Ohio, United States, 44195
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Gregory M. M. Videtic         
Ohio State University Comprehensive Cancer Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Site Public Contact    800-293-5066    Jamesline@osumc.edu   
Principal Investigator: Jose G. Bazan         
The Mark H Zangmeister Center Recruiting
Columbus, Ohio, United States, 43219
Contact: Site Public Contact    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Cleveland Clinic Cancer Center Mansfield Recruiting
Mansfield, Ohio, United States, 44906
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Gregory M. M. Videtic         
Hillcrest Hospital Cancer Center Recruiting
Mayfield Heights, Ohio, United States, 44124
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Gregory M. M. Videtic         
North Coast Cancer Care Recruiting
Sandusky, Ohio, United States, 44870
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Gregory M. M. Videtic         
University Pointe Suspended
West Chester, Ohio, United States, 45069
Cleveland Clinic Wooster Family Health and Surgery Center Recruiting
Wooster, Ohio, United States, 44691
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Gregory M. M. Videtic         
United States, Oklahoma
University of Oklahoma Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Site Public Contact    405-271-8777    ou-clinical-trials@ouhsc.edu   
Principal Investigator: J. S. Thompson         
Mercy Hospital Oklahoma City Recruiting
Oklahoma City, Oklahoma, United States, 73120
Contact: Site Public Contact    405-752-3402      
Principal Investigator: Jay W. Carlson         
United States, Oregon
Good Samaritan Hospital Recruiting
Corvallis, Oregon, United States, 97330
Contact: Site Public Contact    541-768-4352    stmock@samhealth.org   
Principal Investigator: Michael Wahl         
Legacy Mount Hood Medical Center Not yet recruiting
Gresham, Oregon, United States, 97030
Contact: Site Public Contact    503-413-2150      
Principal Investigator: Andrew Y. Kee         
Legacy Good Samaritan Hospital and Medical Center Not yet recruiting
Portland, Oregon, United States, 97210
Contact: Site Public Contact    800-220-4937    cancer@lhs.org   
Principal Investigator: Andrew Y. Kee         
Providence Portland Medical Center Recruiting
Portland, Oregon, United States, 97213
Contact: Site Public Contact    503-215-2614    CanRsrchStudies@providence.org   
Principal Investigator: Dan S. Zuckerman         
Providence Saint Vincent Medical Center Recruiting
Portland, Oregon, United States, 97225
Contact: Site Public Contact    503-215-2614    CanRsrchStudies@providence.org   
Principal Investigator: Dan S. Zuckerman         
United States, Pennsylvania
Bryn Mawr Hospital Recruiting
Bryn Mawr, Pennsylvania, United States, 19010
Contact: Site Public Contact    484-476-2649    turzoe@mlhs.org   
Principal Investigator: Albert S. DeNittis         
Geisinger Medical Center Recruiting
Danville, Pennsylvania, United States, 17822
Contact: Site Public Contact    570-271-5251    HemonCCTrials@geisinger.edu   
Principal Investigator: Fiori Alite         
Delaware County Memorial Hospital Suspended
Drexel Hill, Pennsylvania, United States, 19026
UPMC Pinnacle Cancer Center/Community Osteopathic Campus Recruiting
Harrisburg, Pennsylvania, United States, 17109
Contact: Site Public Contact    717-724-6765    klitchfield@PINNACLEHEALTH.org   
Principal Investigator: Kaihong Mi         
Geisinger Medical Oncology-Lewisburg Recruiting
Lewisburg, Pennsylvania, United States, 17837
Contact: Site Public Contact    570-374-8555    HemonCCTrials@geisinger.edu   
Principal Investigator: Fiori Alite         
Paoli Memorial Hospital Recruiting
Paoli, Pennsylvania, United States, 19301
Contact: Site Public Contact    484-476-2649    turzoe@mlhs.org   
Principal Investigator: Albert S. DeNittis         
Thomas Jefferson University Hospital Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Site Public Contact    215-955-6084      
Principal Investigator: Bo Lu         
Aria Health-Torresdale Campus Recruiting
Philadelphia, Pennsylvania, United States, 19114
Contact: Site Public Contact    215-612-5296      
Principal Investigator: Bo Lu         
Reading Hospital Recruiting
West Reading, Pennsylvania, United States, 19611
Contact: Site Public Contact    610-988-9323      
Principal Investigator: Terrence P. Cescon         
Geisinger Wyoming Valley/Henry Cancer Center Recruiting
Wilkes-Barre, Pennsylvania, United States, 18711
Contact: Site Public Contact    570-271-5251    HemonCCTrials@geisinger.edu   
Principal Investigator: Fiori Alite         
Abington Memorial Hospital-Asplundh Cancer Pavilion Active, not recruiting
Willow Grove, Pennsylvania, United States, 19090
Lankenau Medical Center Recruiting
Wynnewood, Pennsylvania, United States, 19096
Contact: Site Public Contact    484-476-2649    turzoe@mlhs.org   
Principal Investigator: Albert S. DeNittis         
United States, South Carolina
Greenville Health System Cancer Institute-Faris Recruiting
Greenville, South Carolina, United States, 29605
Contact: Site Public Contact    864-241-6251    kwilliams8@ghs.org   
Principal Investigator: Jeffrey K. Giguere         
Greenville Health System Cancer Institute-Eastside Recruiting
Greenville, South Carolina, United States, 29615
Contact: Site Public Contact    864-241-6251    kwilliams8@ghs.org   
Principal Investigator: Jeffrey K. Giguere         
Self Regional Healthcare Recruiting
Greenwood, South Carolina, United States, 29646
Contact: Site Public Contact    864-725-4771    nmcgaha@selfregional.org   
Principal Investigator: Carolyn D. Britten         
Greenville Health System Cancer Institute-Greer Recruiting
Greer, South Carolina, United States, 29650
Contact: Site Public Contact    864-241-6251    kwilliams8@ghs.org   
Principal Investigator: Jeffrey K. Giguere         
Gibbs Cancer Center-Pelham Recruiting
Greer, South Carolina, United States, 29651
Contact: Site Public Contact    864-560-6104    kmertz-rivera@gibbscc.org   
Principal Investigator: Patricia C. Griffin         
The Radiation Oncology Center-Hilton Head/Bluffton Recruiting
Hilton Head Island, South Carolina, United States, 29926
Contact: Site Public Contact    912-819-5704    underberga@sjchs.org   
Principal Investigator: Howard A. Zaren         
Greenville Health System Cancer Institute-Seneca Recruiting
Seneca, South Carolina, United States, 29672
Contact: Site Public Contact    864-241-6251    kwilliams8@ghs.org   
Principal Investigator: Jeffrey K. Giguere         
Spartanburg Medical Center Recruiting
Spartanburg, South Carolina, United States, 29303
Contact: Site Public Contact    864-560-6104    kmertz-rivera@gibbscc.org   
Principal Investigator: Patricia C. Griffin         
Greenville Health System Cancer Institute-Spartanburg Recruiting
Spartanburg, South Carolina, United States, 29307
Contact: Site Public Contact    864-241-6251    kwilliams8@ghs.org   
Principal Investigator: Jeffrey K. Giguere         
United States, South Dakota
Sanford USD Medical Center - Sioux Falls Recruiting
Sioux Falls, South Dakota, United States, 57117-5134
Contact: Site Public Contact    605-312-3320    OncologyClinicalTrialsSF@SanfordHealth.org   
Principal Investigator: Preston D. Steen         
United States, Tennessee
Baptist Memorial Hospital and Cancer Center-Memphis Recruiting
Memphis, Tennessee, United States, 38120
Contact: Site Public Contact    901-226-1366    BCCclintrials@bmhcc.org   
Principal Investigator: Raymond U. Osarogiagbon         
United States, Texas
UT Southwestern/Simmons Cancer Center-Dallas Recruiting
Dallas, Texas, United States, 75390
Contact: Site Public Contact    214-648-7097    canceranswerline@UTSouthwestern.edu   
Principal Investigator: Puneeth Iyengar         
University of Texas Medical Branch Active, not recruiting
Galveston, Texas, United States, 77555-0565
M D Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Site Public Contact    877-632-6789    askmdanderson@mdanderson.org   
Principal Investigator: Saumil Gandhi         
Covenant Medical Center-Lakeside Recruiting
Lubbock, Texas, United States, 79410
Contact: Site Public Contact    806-725-8000    jaccresearch@covhs.org   
Principal Investigator: Kiran K. Yalamanchili         
University of Texas Health Science Center at San Antonio Active, not recruiting
San Antonio, Texas, United States, 78229
United States, Utah
Huntsman Cancer Institute/University of Utah Recruiting
Salt Lake City, Utah, United States, 84112
Contact: Site Public Contact    888-424-2100    cancerinfo@hci.utah.edu   
Principal Investigator: Kristine E. Kokeny         
United States, Virginia
Virginia Commonwealth University/Massey Cancer Center Recruiting
Richmond, Virginia, United States, 23298
Contact: Site Public Contact       mwellons@vcu.edu   
Principal Investigator: Sherman Baker         
United States, Washington
Legacy Salmon Creek Hospital Not yet recruiting
Vancouver, Washington, United States, 98686
Contact: Site Public Contact    503-413-2150      
Principal Investigator: Andrew Y. Kee         
United States, West Virginia
West Virginia University Healthcare Recruiting
Morgantown, West Virginia, United States, 26506
Contact: Site Public Contact    304-293-7374    cancertrialsinfo@hsc.wvu.edu   
Principal Investigator: Malcolm D. Mattes         
United States, Wisconsin
Aurora Cancer Care-Southern Lakes VLCC Recruiting
Burlington, Wisconsin, United States, 53105
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Ellen L. Ziaja         
Marshfield Medical Center-EC Cancer Center Recruiting
Eau Claire, Wisconsin, United States, 54701
Contact: Site Public Contact    800-782-8581    oncology.clinical.trials@marshfieldresearch.org   
Principal Investigator: Patricia K. Lillis         
Aurora Health Center-Fond du Lac Recruiting
Fond Du Lac, Wisconsin, United States, 54937
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Ellen L. Ziaja         
Aurora Health Care Germantown Health Center Recruiting
Germantown, Wisconsin, United States, 53022
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Ellen L. Ziaja         
Aurora Cancer Care-Grafton Recruiting
Grafton, Wisconsin, United States, 53024
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Ellen L. Ziaja         
Saint Vincent Hospital Cancer Center Green Bay Recruiting
Green Bay, Wisconsin, United States, 54301
Contact: Site Public Contact    920-433-8889    Christy.Gilchrist@hshs.org   
Principal Investigator: Matthew L. Ryan         
Saint Vincent Hospital Cancer Center at Saint Mary's Recruiting
Green Bay, Wisconsin, United States, 54303
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Matthew L. Ryan         
Aurora BayCare Medical Center Recruiting
Green Bay, Wisconsin, United States, 54311
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Ellen L. Ziaja         
Aurora Cancer Care-Kenosha South Recruiting
Kenosha, Wisconsin, United States, 53142
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Ellen L. Ziaja         
Gundersen Lutheran Medical Center Recruiting
La Crosse, Wisconsin, United States, 54601
Contact: Site Public Contact    608-775-2385    cancerctr@gundersenhealth.org   
Principal Investigator: Collin D. Driscoll         
Aurora Bay Area Medical Group-Marinette Recruiting
Marinette, Wisconsin, United States, 54143
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Ellen L. Ziaja         
Aurora Cancer Care-Milwaukee Recruiting
Milwaukee, Wisconsin, United States, 53209
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Ellen L. Ziaja         
Aurora Saint Luke's Medical Center Recruiting
Milwaukee, Wisconsin, United States, 53215
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Ellen L. Ziaja         
Aurora Sinai Medical Center Recruiting
Milwaukee, Wisconsin, United States, 53233
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Ellen L. Ziaja         
Vince Lombardi Cancer Clinic - Oshkosh Recruiting
Oshkosh, Wisconsin, United States, 54904
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Ellen L. Ziaja         
Aurora Cancer Care-Racine Recruiting
Racine, Wisconsin, United States, 53406
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Ellen L. Ziaja         
Vince Lombardi Cancer Clinic-Sheboygan Recruiting
Sheboygan, Wisconsin, United States, 53081
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Ellen L. Ziaja         
Marshfield Clinic Stevens Point Center Recruiting
Stevens Point, Wisconsin, United States, 54482
Contact: Site Public Contact    800-782-8581    oncology.clinical.trials@marshfieldresearch.org   
Principal Investigator: Patricia K. Lillis         
Aurora Medical Center in Summit Recruiting
Summit, Wisconsin, United States, 53066
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Ellen L. Ziaja         
Vince Lombardi Cancer Clinic-Two Rivers Recruiting
Two Rivers, Wisconsin, United States, 54241
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Ellen L. Ziaja         
Aurora Cancer Care-Milwaukee West Recruiting
Wauwatosa, Wisconsin, United States, 53226
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Ellen L. Ziaja         
Aurora West Allis Medical Center Recruiting
West Allis, Wisconsin, United States, 53227
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Ellen L. Ziaja         
Canada, Alberta
Cross Cancer Institute Recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Contact: Site Public Contact    780-432-8500      
Principal Investigator: Brock J. Debenham         
Canada, Ontario
London Regional Cancer Program Suspended
London, Ontario, Canada, N6A 4L6
Ottawa Hospital and Cancer Center-General Campus Recruiting
Ottawa, Ontario, Canada, K1H 8L6
Contact: Site Public Contact    613-761-4395      
Principal Investigator: Robert M. MacRae         
Saudi Arabia
King Faisal Specialist Hospital and Research Centre Recruiting
Riyadh, Saudi Arabia, 11211
Contact: Site Public Contact    011-966-1-464-7272 ext 38005      
Principal Investigator: Ameen Al-Omair         
Sponsors and Collaborators
NRG Oncology
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Puneeth Iyengar NRG Oncology

Layout table for additonal information
Responsible Party: NRG Oncology
ClinicalTrials.gov Identifier: NCT03137771     History of Changes
Other Study ID Numbers: NRG-LU002
NCI-2016-00849 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
NRG-LU002 ( Other Identifier: NRG Oncology )
NRG-LU002 ( Other Identifier: CTEP )
U10CA180868 ( U.S. NIH Grant/Contract )
First Posted: May 3, 2017    Key Record Dates
Last Update Posted: June 20, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Gemcitabine
Erlotinib Hydrochloride
Pemetrexed
Docetaxel
Pembrolizumab
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Antineoplastic Agents, Immunological
Protein Kinase Inhibitors